Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 2
1990 1
1991 2
1993 1
1994 1
1995 5
1996 5
1997 2
1998 5
1999 2
2000 2
2001 5
2002 1
2003 2
2004 5
2005 3
2006 8
2007 10
2008 3
2009 8
2010 8
2011 5
2012 6
2013 4
2014 4
2015 3
2016 2
2017 3
2018 4
2019 9
2020 9
2021 17
2022 16
2023 8

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Results by year

Filters applied: . Clear all
Page 1
SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376.
Heilmann E, Costacurta F, Moghadasi SA, Ye C, Pavan M, Bassani D, Volland A, Ascher C, Weiss AKH, Bante D, Harris RS, Moro S, Rupp B, Martinez-Sobrido L, von Laer D. Heilmann E, et al. Among authors: von laer d. Sci Transl Med. 2023 Jan 11;15(678):eabq7360. doi: 10.1126/scitranslmed.abq7360. Epub 2023 Jan 11. Sci Transl Med. 2023. PMID: 36194133 Free PMC article.
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors.
Moghadasi SA, Heilmann E, Khalil AM, Nnabuife C, Kearns FL, Ye C, Moraes SN, Costacurta F, Esler MA, Aihara H, von Laer D, Martinez-Sobrido L, Palzkill T, Amaro RE, Harris RS. Moghadasi SA, et al. Among authors: von laer d. bioRxiv. 2022 Dec 26:2022.08.07.503099. doi: 10.1101/2022.08.07.503099. Preprint. bioRxiv. 2022. PMID: 35982678 Free PMC article. Updated.
Antiviral gene therapy.
von Laer D, Baum C, Protzer U. von Laer D, et al. Handb Exp Pharmacol. 2009;(189):265-97. doi: 10.1007/978-3-540-79086-0_10. Handb Exp Pharmacol. 2009. PMID: 19048204 Review.
Comparison of Four SARS-CoV-2 Neutralization Assays.
Riepler L, Rössler A, Falch A, Volland A, Borena W, von Laer D, Kimpel J. Riepler L, et al. Among authors: von laer d. Vaccines (Basel). 2020 Dec 28;9(1):13. doi: 10.3390/vaccines9010013. Vaccines (Basel). 2020. PMID: 33379160 Free PMC article.
Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection.
Rössler A, Knabl L, von Laer D, Kimpel J. Rössler A, et al. Among authors: von laer d. N Engl J Med. 2022 May 5;386(18):1764-1766. doi: 10.1056/NEJMc2201607. Epub 2022 Mar 23. N Engl J Med. 2022. PMID: 35320661 Free PMC article. No abstract available.
C peptides as entry inhibitors for gene therapy.
Egerer L, Kiem HP, von Laer D. Egerer L, et al. Among authors: von laer d. Adv Exp Med Biol. 2015;848:191-209. doi: 10.1007/978-1-4939-2432-5_10. Adv Exp Med Biol. 2015. PMID: 25757622 Review.
Reduced sensitivity of antibody tests after omicron infection.
Rössler A, Knabl L, Raschbichler LM, Peer E, von Laer D, Borena W, Kimpel J. Rössler A, et al. Among authors: von laer d. Lancet Microbe. 2023 Jan;4(1):e10-e11. doi: 10.1016/S2666-5247(22)00222-1. Epub 2022 Sep 19. Lancet Microbe. 2023. PMID: 36137554 Free PMC article. No abstract available.
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors.
Moghadasi SA, Heilmann E, Khalil AM, Nnabuife C, Kearns FL, Ye C, Moraes SN, Costacurta F, Esler MA, Aihara H, von Laer D, Martinez-Sobrido L, Palzkill T, Amaro RE, Harris RS. Moghadasi SA, et al. Among authors: von laer d. Sci Adv. 2023 Mar 29;9(13):eade8778. doi: 10.1126/sciadv.ade8778. Epub 2023 Mar 29. Sci Adv. 2023. PMID: 36989354 Free PMC article.
163 results